Literature DB >> 23741186

An easy and efficient strategy for KEL genotyping in a multiethnic population.

Carine Prisco Arnoni1, Janaína Guinhem Muniz, Tatiane Aparecida de Paula, Rosangela Duarte de Medeiros Person, Diana Gazito, Wilson Baleotti, José Augusto Barreto, Lilian Castilho, Flavia Roche Moreira Latini.   

Abstract

BACKGROUND: The Kell blood group system expresses high and low frequency antigens with the most important in relation to transfusion including the antithetic KEL1 and KEL2; KEL3 and KEL4; KEL6 and KEL7 antigens. Kell is a clinically relevant system, as it is highly immunogenic and anti-KEL antibodies are associated with hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. Although required in some situations, Kell antigen phenotyping is restricted due to technical limitations. In these cases, molecular approaches maybe a solution. This study proposes three polymerase chain reaction genotyping protocols to analyze the single nucleotide polymorphisms responsible for six Kell antithetic antigens expressed in a Brazilian population.
METHODS: DNA was extracted from 800 blood donor samples and three polymerase chain reaction-restriction fragment length polymorphism protocols were used to genotype the KEL*1/KEL*2, KEL*3/KEL*4 and KEL*6/KEL*7 alleles. KEL*3/KEL*4 and KEL*6/KEL*7 genotyping was standardized using the NlaIII and MnlI restriction enzymes and validated using sequencing. KEL*1/KEL*2 genotyping was performed using a previously reported assay.
RESULTS: KEL genotyping was successfully implemented in the service; the following distribution of KEL alleles was obtained for a population from southeastern Brazil: KEL*1 (2.2%), KEL*2 (97.8%), KEL*3 (0.69%), KEL*4 (99.31%), KEL*6 (2.69%) and KEL*7 (97.31%). Additionally, two individuals with rare genotypes, KEL*1/KEL*1 and KEL*3/KEL*3, were identified.
CONCLUSION: KEL allele genotyping using these methods proved to be reliable and applicable to predict Kell antigen expressions in a Brazilian cohort. This easy and efficient strategy can be employed to provide safer transfusions and to help in rare donor screening.

Entities:  

Keywords:  Erythrocytes; Gene frequency; Kell blood-group system; Molecular biology; Polymerase chain reaction

Year:  2013        PMID: 23741186      PMCID: PMC3672118          DOI: 10.5581/1516-8484.20130029

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


  22 in total

Review 1.  The Kell blood group system: Kell and XK membrane proteins.

Authors:  S Lee; D Russo; C M Redman
Journal:  Semin Hematol       Date:  2000-04       Impact factor: 3.851

2.  AutoDimer: a screening tool for primer-dimer and hairpin structures.

Authors:  Peter M Vallone; John M Butler
Journal:  Biotechniques       Date:  2004-08       Impact factor: 1.993

Review 3.  The value of DNA analysis for antigens of the Kell and Kx blood group systems.

Authors:  Soohee Lee
Journal:  Transfusion       Date:  2007-07       Impact factor: 3.157

4.  Terminology for red cell surface antigens. Makuhari Report.

Authors:  G L Daniels; D J Anstee; J P Cartron; W Dahr; S Henry; P D Issitt; J Jørgensen; W J Judd; L Kornstad; C Levene; C Lomas-Francis; A Lubenko; D Mallory; J M Moulds; J J Moulds; Y Okubo; M Overbeeke; M E Reid; P Rouger; S Seidl; S Sistonen; S Wendel; T Zelinski
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

5.  Haemolytic disease of the newborn due to anti-k.

Authors:  J K Duguid; I M Bromilow
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

6.  Association of XK and Kell blood group proteins.

Authors:  D Russo; C Redman; S Lee
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

7.  Hemolytic disease of the newborn due to anti-Js a .

Authors:  L M Donovan; K L Tripp; J E Zuckerman; A A Konugres
Journal:  Transfusion       Date:  1973 May-Jun       Impact factor: 3.157

8.  Routine use of DNA testing for red cell antigens in blood centres.

Authors:  Christof Jungbauer
Journal:  Transfus Apher Sci       Date:  2011-07-07       Impact factor: 1.764

9.  Hydrops fetalis caused by a blood group antibody usually undetected in routine screening.

Authors:  J Smoleniec; N Anderson; G Poole
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

10.  KEL6 and KEL7 genotyping with sequence-specific primers.

Authors:  Keli J Renoud; Kathleen Barracchini; Karen M Byrne; Sharon Adams; Angela Pickett; Lorraine Caruccio; David F Stroncek
Journal:  Transfusion       Date:  2006-09       Impact factor: 3.157

View more
  5 in total

1.  Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein.

Authors:  Stella Maris Mattaloni; Carine Arnoni; Rosario Céspedes; Claudia Nonaka; Carolina Trucco Boggione; Melina Eliana Luján Brajovich; Andrea Trejo; Néstor Zani; Claudia Silvia Biondi; Lilian Castilho; Carlos Miquel Cotorruelo
Journal:  Transfus Med Hemother       Date:  2016-11-02       Impact factor: 3.747

2.  Risk Minimization of Hemolytic Disease of the Fetus and Newborn Using Droplet Digital PCR Method for Accurate Fetal Genotype Assessment of RHD, KEL, and RHCE from Cell-Free Fetal DNA of Maternal Plasma.

Authors:  Radek Vodicka; Jana Bohmova; Iva Holuskova; Eva Krejcirikova; Martin Prochazka; Radek Vrtel
Journal:  Diagnostics (Basel)       Date:  2021-04-28

3.  Molecular assays as tools to facilitate new discoveries and to enhance immunohematology in daily transfusion practice.

Authors:  Maria Rios
Journal:  Rev Bras Hematol Hemoter       Date:  2013

4.  Genetic variability of blood groups in southern Brazil.

Authors:  Gabriela Waskow; Mirelen Moura de Oliveira Rodrigues; Gabriela Höher; Tor Onsten; Juliana Dal-Ri Lindenau; Marilu Fiegenbaum; Silvana Almeida
Journal:  Genet Mol Biol       Date:  2020-05-29       Impact factor: 1.771

5.  Blood group genotyping in alloimmunized multi-transfused thalassemia patients from Iran.

Authors:  Reyhaneh Sarihi; Arezoo Oodi; Raziyeh Dadkhah Tehrani; Seyedeh Farzaneh Jalali; Fahimeh Mardani; Azita Azarkeivan; Samira Gudarzi; Naser Amirizadeh
Journal:  Mol Genet Genomic Med       Date:  2021-05-08       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.